SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Sofia Michael J. (Last) (First) (Middle) C/O TEKMIRA PHARMACEUTICALS CORPORATION 100-8900 GLENLYON PARKWAY (Street) BURNABY A1 V5J 5J8 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/04/2015	3. Issuer Name and Ticker or Trading Symbol TEKMIRA PHARMACEUTICALS Corp [ TKMR ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Scientific Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,563,403(1)	D
Common Stock	201,412(2)	I(2)	By Trust(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person held 1,552,440 shares of common stock of OnCore Biopharma, Inc. ("OnCore"). Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated January 11, 2015, by and among the issuer, TKM Acquisition Corporation and OnCore (the "Merger"), each issued and outstanding share of OnCore common stock was converted into 1.007062 common shares (rounded down) of the issuer. The closing of the Merger occurred on March 4, 2015.

2. These shares are owned by the Irrevocable Deed of Trust of Michael J. Sofia dated December 23, 2014 (the "Trust"). The reporting person's wife and adult children are both the Trustees and the beneficiaries of the Trust. The Trust held 200,000 shares of common stock of OnCore prior to the Merger. In connection with the Merger, the Trust acquired shares of the issuer at the same conversion rate as described in footnote (1) herein. The reporting person disclaims beneficial ownership of the shares owned by the Trust and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/Alison Haggerty, Attorney-in-Fact	03/16/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.